Carbon ion re-irradiation after radiotherapy is one of the most common questions we receive when cancer grows back in an area that has already been irradiated. Carbon ion centers in Japan, Germany and China have treated the same site again (re-irradiation) in routine care and in studies. In Heidelberg, Germany, 229 patients with recurrent head and neck cancer received carbon ion re-irradiation, and a prospective study at Gunma University in Japan reported a 2-year overall survival of 67% in 22 patients. Eligibility depends on whether the recurrence is confined to one site, how long it has been since the first treatment, and how much dose nearby organs have already received. This article covers the results, the criteria, the documents to prepare and the cost. To check eligibility based on your previous radiotherapy records, please send them via our re-irradiation eligibility and cost consultation.
Can an irradiated area be treated again?
After conventional X-ray radiotherapy, normal tissues such as skin, mucosa, the spinal cord and blood vessels have already received a certain dose. Treating the same area again in the same way can easily exceed what those tissues tolerate, so many patients are told that "radiation is no longer an option" when the cancer recurs. Surgery is considered first when feasible, but many patients cannot have surgery because of tumor location or general health.
Carbon ions release most of their energy at a set depth and then stop (the Bragg peak), with a narrow lateral spread. This makes it easier to concentrate a high dose on the tumor while steering around already-stressed tissue. Carbon ions also damage cells more strongly than X-rays and remain effective in low-oxygen tumors. Tumors that regrow after a first course of radiation are often radioresistant, which is why these properties attract attention in re-irradiation. See What Is Carbon Ion Therapy? for the principle.
What results have been reported?
Most re-irradiation data come from head and neck cancer, with Japanese reports also covering lung cancer and pelvic recurrences. A 2022 review (Frontiers in Oncology) co-written by physicians from QST Hospital in Japan and Heidelberg University Hospital summarized the head and neck results; lung and multi-site results were published directly by Japanese centers.
| Study (center, year) | Patients | Number | Key results |
|---|---|---|---|
| Held et al. (Heidelberg, Germany, IJROBP) | Recurrent head and neck cancer | 229 | Median survival 26.1 months; 1-year survival 72% |
| Gao et al. (Shanghai, China) | Recurrent head and neck cancer (78.1% nasopharyngeal) | 141 | 1-year local control 84.9%; 1-year survival 95.9% |
| Hu et al. (Shanghai, China) | Recurrent nasopharyngeal cancer | 75 | 1-year survival 98.1%; 1-year local recurrence-free survival 86.6% |
| Vischioni et al. (CNAO, Italy) | Mainly recurrent salivary gland cancer | 51 | 1-year survival 90.2%; 2-year 64% |
| Karube et al. (QST Hospital, Japan, 2017) | Stage I non-small cell lung cancer recurring after carbon ion therapy | 29 | 2-year local control 66.9%; 2-year survival 69.0% |
| Gunma University prospective study (2019) | Isolated recurrence in an irradiated site (rectal, sarcoma, lung, liver, etc.) | 22 | 2-year local control 60%; 2-year survival 67% |
In the Heidelberg study, patients with adenoid cystic carcinoma had a longer median survival of about 33.6 months. In the QST lung study, the median age at re-irradiation was 74 (up to 90), and no grade 3 or higher treatment-related side effects were reported. This shows that patients whose first treatment was carbon ion therapy can be treated with carbon ions again.
Most of these are single-center retrospective analyses with different cancer types and dose schedules, so rather than comparing numbers directly, they are best read as evidence that patients with recurrences unsuitable for surgery have a renewed chance of tumor control. Pelvic recurrence of rectal cancer is covered in Rectal Cancer Recurrence and Carbon Ion Therapy.
Who is a candidate for carbon ion re-irradiation?
The criteria used in the Gunma prospective study help patients and families gauge their situation.
- Confirmed recurrence measurable on CT or MRI
- A single, isolated recurrence in the previously irradiated site (not widely spread)
- Performance status 0 to 2 (able to walk and care for oneself)
- Life expectancy over 6 months
- No direct invasion of the gastrointestinal tract or a major blood vessel
- Recurrence within 3 months of the first radiotherapy excluded; no uncontrolled infection or severe coexisting disease
Timing matters. In Heidelberg, patients with more than 12 months between treatments did better, and in a Japanese study an interval under 24 months was linked to poorer results. Several studies also found better outcomes with smaller tumor volumes, so starting a consultation early, while the recurrence is small, is an advantage.
How are side effects managed?
Because normal tissue receives a second dose, physicians calculate the cumulative dose from both treatments for each organ and set limits. For example, the Heidelberg trial criteria cap the cumulative spinal cord dose at 50 Gy if the interval is 24 months or less and 60 Gy if it is longer (EQD2).
In head and neck re-irradiation, grade 3 or higher late side effects were 14.5–17.5% in most studies. The main concerns are soft tissue necrosis and carotid hemorrhage; carotid hemorrhage was below 5% in most studies, and CNAO in Italy reported avoiding it with a technique that sets separate carotid dose limits. In the Gunma study, 4 of 22 patients had grade 3 late effects (mainly ureteral narrowing) and none had grade 4 or higher. After treatment, the Japanese center and the referring hospital share follow-up to catch changes early.
Documents and carbon ion therapy cost
QST Hospital asks patients to bring a referral letter, CT/MRI images and the pathology report to the first visit. For re-irradiation, previous radiotherapy records are also needed so physicians can calculate cumulative dose.
| Document | Why it is needed |
|---|---|
| Radiotherapy summary (dates, total dose, fractions, treated site) | Cumulative dose to normal organs and treatment interval |
| Radiotherapy plan data (DICOM-RT files if possible) | Overlaying dose distributions to find safe beam angles |
| Recent CT/MRI/PET images showing the recurrence (CD) | Confirming a single site and no GI or vessel invasion |
| Biopsy and pathology report | Confirming recurrence and cancer type |
| Referral letter, recent blood tests, medication list | General health and coexisting conditions |
According to QST Hospital's guidance for overseas patients, carbon ion radiotherapy costs 5.786 million yen including tax; hospitalization, outpatient visits and tests are charged separately at 33 yen per medical fee point (tax included). Medical coordinator fees are not included (checked October 23, 2026). No separate re-irradiation price is published, so the actual estimate is confirmed after the hospital's review. Preparation usually starts 1–2 weeks before treatment, and about 10 days pass between the planning CT and the first session. See Carbon Ion Therapy Cost and Japanese Institutions.
Re-irradiation review starts with your previous treatment records. Prepare your radiotherapy summary and recent images and contact us, or call +82-2-517-5117.
FAQ
I have already had radiotherapy. Can I still receive carbon ion therapy?
In some cases, yes. When the recurrence is confined to one site, enough time has passed since the first treatment and cumulative doses to nearby organs stay within limits, carbon ion centers in Japan, Germany and China have performed re-irradiation. The treating physician makes the final decision after reviewing images and prior records.
How long after the first radiotherapy must I wait?
There is no single rule. The Gunma study excluded recurrences within 3 months, and in Heidelberg patients with intervals over 12 months did better. A longer interval gives normal tissue more time to recover and makes planning easier.
Can I be re-treated if my first treatment was carbon ion therapy?
QST Hospital re-treated 29 patients with stage I lung cancer recurring after carbon ion therapy and reported 2-year local control of 66.9% and 2-year survival of 69.0%. Eligibility depends on the recurrence site and the first dose.
Does re-irradiation cost differ from the first treatment?
QST Hospital's published price for overseas patients lists a single amount of 5.786 million yen (tax included) for carbon ion radiotherapy, with no separate re-irradiation price. Medical and test fees, accommodation and interpreting are added, so confirm the total with an estimate.
Related articles
Wondering if carbon ion therapy is possible for you, and what it costs?
We help you prepare consultations with Japanese institutions and provide medical interpreting.
Free consultationCall +82-2-517-5117Sources
- Bhattacharyya T et al. Emerging Role of Carbon Ion Radiotherapy in Reirradiation of Recurrent Head and Neck Cancers (Frontiers in Oncology, 2022)
- Held T et al. Carbon Ion Re-Irradiation for Recurrent Head-and-Neck Cancer: A Single-Institutional Experience (IJROBP)
- Karube M et al. Carbon-ion re-irradiation for recurrences after initial treatment of stage I NSCLC with carbon-ion radiotherapy (Radiotherapy and Oncology, 2017)
- Gunma University. Prospective Study of Isolated Recurrent Tumor Re-irradiation With Carbon-Ion Beams (Frontiers in Oncology, 2019)
- QST Hospital — Process of carbon ion radiotherapy
- QST Hospital — For patients from abroad (cost)
General information based on public sources; not a substitute for diagnosis or treatment. Eligibility is decided by the treating physicians. Written by the FTH editorial team.